Predina et al. demonstrated in a murine model that intratumoral immunotherapy was highly effective in reducing tumor volume with enhanced CD8+ T-cell antitumor activity in early stage disease and less so in advanced disease [182]. This evidence concerns the gene CD8A and neoplasm.